drugset / Trial / NCT01365598

Evaluation of the Gametocytocidal Efficacy and Safety of Primaquine in Uncomplicated Falciparum Malaria in Uganda

NCT01365598

RandomizedParallel-groupTriple-blindPrevention

Summary

The purpose of this study is to evaluate the safety and efficacy of lower doses of primaquine compared to the dose recommended by the WHO for reducing P. falciparum gametocytes in the infected human host to prevent transmission of falciparum malaria to the anopheles mosquito vector.

Timeline

Start
2011-12
Primary completion
2013-03
Completion
2013-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Primaquine Small molecule 0.1 mg/kg Oral
Subject Primaquine Small molecule 0.4 mg/kg Oral
Subject Primaquine Small molecule 0.75 mg/kg Oral